Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD‐1/PD‐L1 Blockade Therapies

Background Programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) blockade immunotherapies have changed the landscape of cancer therapy. However, the main limitation of these therapies is the lack of definitively predictive biomarkers to predict treatment response. Whether PD‐L1 expression...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2021-12, Vol.26 (12), p.e2227-e2238
Main Authors: Tan, Zhaoli, Yue, Chunyan, Ji, Shoujian, Zhao, Chuanhua, Jia, Ru, Zhang, Yun, Liu, Rongrui, Li, Da, Yu, Qian, Li, Ping, Hu, Zhiyuan, Yang, Yanlian, Xu, Jianming
Format: Article
Language:English
Subjects:
Advanced solid cancer
Analysis
Anti‐PD‐1/PD‐L1 mAbs
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - metabolism
Biological markers
Cancer
Care and treatment
Circulating tumor cells
Dosage and administration
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Immuno‐Oncology
Monoclonal antibodies
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplastic Cells, Circulating
Prognosis
Programmed death‐ligand 1
Semiquantitative analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) blockade immunotherapies have changed the landscape of cancer therapy. However, the main limitation of these therapies is the lack of definitively predictive biomarkers to predict treatment response. Whether PD‐L1 expression on circulating tumor cells (CTCs) is associated with the clinical outcomes of immunotherapy remains to be extensively investigated. Materials and Methods One hundred fifty‐five patients with different advanced cancers were enrolled in this study and treated with anti‐PD‐1/PD‐L1 monoclonal antibodies. Using the Pep@MNPs method, CTCs were isolated and enumerated. The PD‐L1 expression levels were analyzed by an immunofluorescence assay for semiquantitative assessment with four categories (negative, low, medium, and high). Results Prior to immunotherapy, 81.93% (127/155) of patients had PD‐L1‐positive CTCs, and 71.61% (111/155) had at least one PD‐L1‐high CTC. The group with PD‐L1‐positive CTCs had a higher disease control rate (DCR) (71.56%, 91/127), with a DCR of only 39.29% (11/28) for the remaining individuals (p = .001). The objective response rate and DCR in PD‐L1‐high patients were higher than those in the other patients (32.44% vs. 13.64%, p = .018 and 75.68% vs. 40.91%, p 
ISSN:1083-7159
1549-490X
DOI:10.1002/onco.13981